The Akt/NF-κB pathway has been reported to regulate the cisplatin sensitivity in lung adenocarcinoma cells [16], cisplatin sensitivity in human breast cancer cells [17], chemosensitivity to cisplatin in human NSCLS cells [18], cisplatin resistance in gastric cancer cells [19], and carboplatin sensitivity in prostate cancer [20]. Here, AKT1 is linked to lung adenocarcinoma.